• Cellvizio®
    • Overview
    • Education
    • Economics
    • Indications
      • Gastroenterology
        • Barrett’s Esophagus
        • Pancreatic Cysts
        • Gastric Disease
        • Inflammatory Bowel Diseases
        • Irritable Bowel Syndrome – Food Intolerance
        • Bilio-Pancreatic Strictures
        • Colorectal Lesions
      • Pulmonology
        • Lung Nodules
        • Lung Transplant
      • Urology
  • Investors
    • Overview
    • Events and Presentations
    • Financials
    • Governance
  • About Us
    • Our Story
    • Team
      • Board of Directors
      • Leadership Team
    • Join Us
    • Commercial network
  • Newsroom
    • News
    • Events
    • Press Coverage
  • INT
    • US
    • FR
Needle-based confocal laser endomicroscopy accurately provides pancreatic cystic lesions’ histology: 2 study insights

Needle-based confocal laser endomicroscopy accurately provides pancreatic cystic lesions’ histology: 2 study insights

by Zina | Mar 29, 2017 | Press Coverage

A study published in Gastrointestinal Endoscopy found endoscopic ultrasound guided needle-based confocal laser endomicroscopy accurately provides pancreatic cystic lesions' histology. Columbus-based Ohio State University Gastroenterologist...
New Peer-Reviewed Publication Reports Further External Validation of Unmatched Cellvizio Endomicroscopy Performance and Inter-Observer Agreement in the Characterization of Pancreatic Cysts

New Peer-Reviewed Publication Reports Further External Validation of Unmatched Cellvizio Endomicroscopy Performance and Inter-Observer Agreement in the Characterization of Pancreatic Cysts

by Zina | Mar 27, 2017 | News

Clinical study published in GI Endoscopy this month, performed by the Wexner Medical Center at Ohio State University, a National Pancreas Foundation Center of Excellence Blinded trial shows 95% accuracy of Cellvizio for malignant pancreatic cysts and 98% for benign...

Mauna Kea Technologies confirms its eligibility to the French PEA-PME investment vehicles for 2017/2018

by Zina | Mar 20, 2017 | News

Paris, March 20th 2017 – Mauna Kea Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : MKEAY), inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy platform, today confirmed it is eligible to the PEA-PME investment vehicles,...
Mauna Kea appoints Jennifer F. Tseng, M.D. to Board of Directors

Mauna Kea appoints Jennifer F. Tseng, M.D. to Board of Directors

by Zina | Mar 13, 2017 | News

Leading Surgical Oncologist and GI Specialist to Add Clinical Expertise Paris, France and Cambridge, MA, USA, March 13, 2017 – Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy...

Superiority of Endomicroscopy for the Diagnosis of Gastric Cancer Highlighted in a Peer-Reviewed Publication Comparing Advanced Imaging Technologies

by Zina | Mar 2, 2017 | News

Meta-Analysis Shows Superiority Compared to Other Imaging Modalities Paris, March 2, 2017 – Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) platform, today announced a...
« Older Entries
Next Entries »

Articles récents

  • EUS-ENDO Congress – Strasbourg, France
  • See Beyond the Surface: How Cellvizio® Redefines Accuracy for Detecting and Treating Cancers
  • Mauna Kea Technologies Reports First Half 2025 Revenue 
  • Mauna Kea Technologies Enters Australian Market with Endotherapeutics Partnership 
  • Mauna Kea Technologies Strengthens its Leading Role in the AI-based Endomicroscopic Imaging Ecosystem with its 14th Patent Granted in the U.S. 

Commentaires récents

No comments to show.

Company Info

About Us

Join Us

Contact Us

Legal

Legal notice

Cookies policy

Privacy policy

Our websites

Cellvizio.net

cell-tolerance.com

Diagnosingbarretts.org

Diagnosingpancreaticcysts.org

Follow us

  • Follow
  • Follow
  • Follow
  • Follow
Manage Consent
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
View preferences
{title} {title} {title}